Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2015 Feb 16;284(1):79–91. doi: 10.1016/j.taap.2015.02.009

Fig. 2.

Fig. 2

Relative expression levels [mRNA, protein and testosterone 2α-hydroxylase (T 2αOH) catalytic activity] of the paramount male-specific CYP2C11 isoform in hepatocytes from adult male rats that were either neonatally administered MSG or vehicle. Neonatally-treated pups were injected with either MSG (2mg/g bd wt) or equivalent doses of vehicle (Control) on postnatal days 1, 3, 5, 7, and 9. A. CYP2C11 levels in freshly isolated preplated hepatocytes. Results are presented as a percentage of mRNA or protein in hepatocytes from control rats arbitrarily designated 100%. Values are means ±SD of at least 7 rats/data point. *P<0.01 vs control rats. B. Hepatocytes from the same animal were exposed to either the episodic male-like GH profile or the hormone’s vehicle, or the continuous female-like GH profile or vehicle for 6 days. Results are presented as a percentage of mRNA or protein in hepatocytes exposed to vehicle administered in an episodic male-like profile, arbitrarily designated 100%. Values are means ±SD of at least 7 rats/data point. *P<0.01 vs hepatocytes exposed to the episodic male-like vehicle profile from rats of the same neonatal treatment, i.e. Control or MSG.